After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?
Dear Editor, the number of cases of cancer patients diagnosed as having immune checkpoint inhibitor-mediated polymyalgia rheumatica has been steadily rising in published reports. However, the lack of a validated scale or algorithm is still a relevant methodological limit in diagnosing this nosologi...
Saved in:
| Main Authors: | Ciro Manzo, Marco Isetta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-03-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports
by: Ciro Manzo, et al.
Published: (2025-04-01) -
POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01) -
REVIEW OF RECOMMENDATIONS FOR THE MANAGEMENT OF POLYMYALGIA RHEUMATICA (ACR/EULAR 2015)
by: M. T. Vatutin, et al.
Published: (2016-03-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01) -
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)